Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1996 Mar;87(3):348–354.

Engineering of recombinant soluble CD46: an inhibitor of complement activation.

D Christiansen 1, J Milland 1, B R Thorley 1, I F McKenzie 1, P L Mottram 1, L J Purcell 1, B E Loveland 1
PMCID: PMC1384101  PMID: 8778018

Abstract

Human CD46 (membrane cofactor protein) is a type 1 glycoprotein that functions to protect autologous cells from complement-mediated damage by binding C3b and C4b for their factor I-mediated cleavage. We now describe the production and function of recombinant soluble CD46 (rsCD46), which was produced as a truncated form by mutagenesis using the splice overlap extension polymerase chain reaction, by inserting a translational stop codon into the CD46 cDNA at the junction of the transmembrane and extracellular domains. After transfection of an expression construct into 293-EBNA (Epstein-Barr nuclear antigen)-transformed cells, secretion of rsCD46 protein was detected by immunoradiometric assay using monoclonal antibodies. Following a single-step immunoaffinity purification, the protein resolved as a single band of approximately 56,000 MW on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The purified rsCD46 (51 micrograms/ml) protected Chinese hamster ovary (CHO) cells from lysis initiated by a high titre rabbit anti-CHO antibody and complement from rabbit or human. The protection was specifically mediated by rsCD46 because the monoclonal antibody M177, which blocks interaction between CD46 and C3b/C4b, abrogated the protection. The results demonstrate that rsCD46 is effective as a fluid-phase regulator of complement activation on cell surfaces, even when initiated by the classical complement pathway. The in vivo efficacy of rsCD46 was investigated using a mouse heart to rat xenograft model. Administration of a bolus injection of rsCD46 was effective at delaying hyperacute graft rejection. These data suggest that rsCD46 may have a role as a therapeutic agent.

Full text

PDF
348

Images in this article

351Figure 2
on p.351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams E. M., Brown M. C., Nunge M., Krych M., Atkinson J. P. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol. 1991 Nov 1;147(9):3005–3011. [PubMed] [Google Scholar]
  2. Bergelson J. M., Chan M., Solomon K. R., St John N. F., Lin H., Finberg R. W. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6245–6248. doi: 10.1073/pnas.91.13.6245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boyer V., Delibrias C., Noraz N., Fischer E., Kazatchkine M. D., Desgranges C. Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand J Immunol. 1992 Dec;36(6):879–883. doi: 10.1111/j.1365-3083.1992.tb03150.x. [DOI] [PubMed] [Google Scholar]
  4. Carrington C. A., Richards A. C., Cozzi E., Langford G., Yannoutsos N., White D. J. Expression of human DAF and MCP on pig endothelial cells protects from human complement. Transplant Proc. 1995 Feb;27(1):321–323. [PubMed] [Google Scholar]
  5. Colten H. R., Rosen F. S. Complement deficiencies. Annu Rev Immunol. 1992;10:809–834. doi: 10.1146/annurev.iy.10.040192.004113. [DOI] [PubMed] [Google Scholar]
  6. Davies A., Lachmann P. J. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res. 1993;12(3):258–275. doi: 10.1007/BF02918257. [DOI] [PubMed] [Google Scholar]
  7. Delibrias C. C., Kazatchkine M. D., Fischer E. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol. 1993 Aug;38(2):183–189. doi: 10.1111/j.1365-3083.1993.tb01711.x. [DOI] [PubMed] [Google Scholar]
  8. Dörig R. E., Marcil A., Chopra A., Richardson C. D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993 Oct 22;75(2):295–305. doi: 10.1016/0092-8674(93)80071-l. [DOI] [PubMed] [Google Scholar]
  9. Fingeroth J. D., Weis J. J., Tedder T. F., Strominger J. L., Biro P. A., Fearon D. T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4510–4514. doi: 10.1073/pnas.81.14.4510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gill S. C., von Hippel P. H. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem. 1989 Nov 1;182(2):319–326. doi: 10.1016/0003-2697(89)90602-7. [DOI] [PubMed] [Google Scholar]
  11. Hara T., Kuriyama S., Kiyohara H., Nagase Y., Matsumoto M., Seya T. Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects. Clin Exp Immunol. 1992 Sep;89(3):490–494. doi: 10.1111/j.1365-2249.1992.tb06986.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hogarth P. M., Edwards J., McKenzie I. F., Goding J. W., Liew F. Y. Monoclonal antibodies to the murine Ly-2.1 cell surface antigen. Immunology. 1982 May;46(1):135–144. [PMC free article] [PubMed] [Google Scholar]
  13. Horton R. M., Cai Z. L., Ho S. N., Pease L. R. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques. 1990 May;8(5):528–535. [PubMed] [Google Scholar]
  14. Hourcade D., Holers V. M., Atkinson J. P. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989;45:381–416. doi: 10.1016/s0065-2776(08)60697-5. [DOI] [PubMed] [Google Scholar]
  15. Johnstone R. W., Loveland B. E., McKenzie I. F. Identification and quantification of complement regulator CD46 on normal human tissues. Immunology. 1993 Jul;79(3):341–347. [PMC free article] [PubMed] [Google Scholar]
  16. Kalvakolanu D. V., Bandyopadhyay S. K., Tiwari R. K., Sen G. C. Enhancement of expression of exogenous genes by 2-aminopurine. Regulation at the post-transcriptional level. J Biol Chem. 1991 Jan 15;266(2):873–879. [PubMed] [Google Scholar]
  17. Kojima A., Iwata K., Seya T., Matsumoto M., Ariga H., Atkinson J. P., Nagasawa S. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol. 1993 Aug 1;151(3):1519–1527. [PubMed] [Google Scholar]
  18. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  19. Loveland B. E., Johnstone R. W., Russell S. M., Thorley B. R., McKenzie I. F. CD46 (MCP) confers protection from lysis by xenogeneic antibodies. Transplant Proc. 1993 Feb;25(1 Pt 1):396–397. [PubMed] [Google Scholar]
  20. Moran P., Beasley H., Gorrell A., Martin E., Gribling P., Fuchs H., Gillett N., Burton L. E., Caras I. W. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol. 1992 Sep 1;149(5):1736–1743. [PubMed] [Google Scholar]
  21. Morrissey J. H. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981 Nov 1;117(2):307–310. doi: 10.1016/0003-2697(81)90783-1. [DOI] [PubMed] [Google Scholar]
  22. Mottram P. L., Smith J. A., Mason A., Mirisklavos A., Dumble L. J., Clunie G. J. Electrocardiographic monitoring of cardiac transplants in mice. Cardiovasc Res. 1988 May;22(5):315–321. doi: 10.1093/cvr/22.5.315. [DOI] [PubMed] [Google Scholar]
  23. Naniche D., Varior-Krishnan G., Cervoni F., Wild T. F., Rossi B., Rabourdin-Combe C., Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993 Oct;67(10):6025–6032. doi: 10.1128/jvi.67.10.6025-6032.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Oglesby T. J., Allen C. J., Liszewski M. K., White D. J., Atkinson J. P. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med. 1992 Jun 1;175(6):1547–1551. doi: 10.1084/jem.175.6.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pruitt S. K., Baldwin W. M., 3rd, Marsh H. C., Jr, Lin S. S., Yeh C. G., Bollinger R. R. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation. 1991 Nov;52(5):868–873. doi: 10.1097/00007890-199111000-00022. [DOI] [PubMed] [Google Scholar]
  26. Pruitt S. K., Kirk A. D., Bollinger R. R., Marsh H. C., Jr, Collins B. H., Levin J. L., Mault J. R., Heinle J. S., Ibrahim S., Rudolph A. R. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation. 1994 Feb;57(3):363–370. doi: 10.1097/00007890-199402150-00009. [DOI] [PubMed] [Google Scholar]
  27. Purcell D. F., Russell S. M., Deacon N. J., Brown M. A., Hooker D. J., McKenzie I. F. Alternatively spliced RNAs encode several isoforms of CD46 (MCP), a regulator of complement activation. Immunogenetics. 1991;33(5-6):335–344. doi: 10.1007/BF00216692. [DOI] [PubMed] [Google Scholar]
  28. Rey-Campos J., Rubinstein P., Rodriguez de Cordoba S. A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP. J Exp Med. 1988 Feb 1;167(2):664–669. doi: 10.1084/jem.167.2.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Russell S. M., Sparrow R. L., McKenzie I. F., Purcell D. F. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur J Immunol. 1992 Jun;22(6):1513–1518. doi: 10.1002/eji.1830220625. [DOI] [PubMed] [Google Scholar]
  30. Seya T., Ballard L. L., Bora N. S., Kumar V., Cui W., Atkinson J. P. Distribution of membrane cofactor protein of complement on human peripheral blood cells. An altered form is found on granulocytes. Eur J Immunol. 1988 Aug;18(8):1289–1294. doi: 10.1002/eji.1830180821. [DOI] [PubMed] [Google Scholar]
  31. Seya T., Hara T., Matsumoto M., Sugita Y., Akedo H. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J Exp Med. 1990 Dec 1;172(6):1673–1680. doi: 10.1084/jem.172.6.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Seya T., Hara T., Uenaka A., Nakayama E., Akedo H. Application of protein A-rosette assay for screening of monoclonal antibodies to human complement regulatory proteins. Complement Inflamm. 1990;7(2):78–89. doi: 10.1159/000463132. [DOI] [PubMed] [Google Scholar]
  33. Sparrow R. L., McKenzie I. F. Hu Ly-m5: a unique antigen physically associated with HLA molecules. Hum Immunol. 1983 May;7(1):1–15. doi: 10.1016/0198-8859(83)90002-2. [DOI] [PubMed] [Google Scholar]
  34. Weisman H. F., Bartow T., Leppo M. K., Marsh H. C., Jr, Carson G. R., Concino M. F., Boyle M. P., Roux K. H., Weisfeldt M. L., Fearon D. T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990 Jul 13;249(4965):146–151. doi: 10.1126/science.2371562. [DOI] [PubMed] [Google Scholar]
  35. Yeh C. G., Marsh H. C., Jr, Carson G. R., Berman L., Concino M. F., Scesney S. M., Kuestner R. E., Skibbens R., Donahue K. A., Ip S. H. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats. J Immunol. 1991 Jan 1;146(1):250–256. [PubMed] [Google Scholar]
  36. Zehr K. J., Herskowitz A., Lee P. C., Kumar P., Gillinov A. M., Baumgartner W. A. Neutrophil adhesion and complement inhibition prolongs survival of cardiac xenografts in discordant species. Transplantation. 1994 Mar 27;57(6):900–906. doi: 10.1097/00007890-199403270-00023. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES